Study guide

3.5 Medication-Related Osteonecrosis of the Jaw (MRONJ) Risk & Management

Australian Dental Council ADC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Examination Overview

1.1 ADC Written Examination Structure, Scoring Clusters & Australian Practice Context 1.2 Clinical Scenario Reasoning & Australian Therapeutic Guidelines Alignment

2 Chapter 2: Restorative Dentistry & Fixed Prosthodontics

2.1 Minimal Intervention Dentistry, Caries Risk & Lesion Management 2.2 Direct Restorative Materials, Resin Composites & Dental Amalgam 2.3 Indirect Restorations, Crown Preparation, Veneers & Onlays 2.4 Dental Adhesion, Etch-and-Rinse vs Self-Etch Systems & Hybrid Layer 2.5 Diagnosis & Management of Tooth Wear (Erosion, Attrition, Abrasion, Abfraction)

3 Chapter 3: Dental Pharmacology & Therapeutic Guidelines

3.1 Local Anaesthetic Agents, Vasoconstrictors & Injection Techniques 3.2 Dental Analgesia Protocols, NSAIDs, Paracetamol & Opioid Stewardship 3.3 Dental Antibiotic Prescribing, Prophylaxis & Therapeutic Guidelines 3.4 Management of Patients on Anticoagulants & Antiplatelet Therapy 3.5 Medication-Related Osteonecrosis of the Jaw (MRONJ) Risk & Management

4 Chapter 4: General Medicine & Medically Compromised Patients

4.1 Dental Office Medical Emergencies, Anaphylaxis & Resuscitation Protocols 4.2 Management of Patients with Cardiovascular, Respiratory & Renal Diseases 4.3 Special Needs Dentistry, Geriatric Care & Dental Management in Pregnancy 4.4 Infective Endocarditis Prophylaxis & Cardiac Risk Assessment

5 Chapter 5: Oral Medicine & Oral Pathology

5.1 Ulcerative, Vesiculobullous & Immune-Mediated Oral Mucosal Diseases 5.2 Oral Potentially Malignant Disorders (OPMDs) & Oral Cancer Screening 5.3 Salivary Gland Disorders, Sialadenitis & Cysts of the Jaws 5.4 Oral Biopsy Indications, Diagnostic Pathways & Specialist Referral

6 Chapter 6: Endodontics

6.1 Pulpal and Periapical Diagnostic Classification & Diagnostic Testing 6.2 Canal Instrumentation, Working Length & Irrigation Protocols 6.3 Root Canal Obturation, Endodontic Retreatment & Failure Analysis 6.4 Endodontic Management of Traumatic Dental Injuries & Vital Pulp Therapy

7 Chapter 7: Oral Surgery

7.1 Surgical & Simple Exodontia Techniques & Intraoperative Complications 7.2 Assessment & Surgical Management of Impacted Third Molars 7.3 Oroantral Communication, Displacement & Trigeminal Nerve Injury Prevention 7.4 Management of Spreading Odontogenic Infections & Fascial Space Abscesses

8 Chapter 8: Paediatric Dentistry & Orthodontics

8.1 Primary Tooth Pulpotomy, Pulpectomy & Stainless Steel Crown Restoration 8.2 Early Childhood Caries, Space Maintenance & Traumatic Primary Dentition 8.3 Malocclusion Classification, Etiology & Interceptive Orthodontic Management 8.4 Non-Pharmacological Behaviour Guidance, Child Protection & Consent

9 Chapter 9: Periodontics

9.1 2018 Periodontal Staging, Grading & Risk Factor Assessment 9.2 Subgingival Debridement, Plaque Control & Antimicrobial Adjuncts 9.3 Periodontal Surgical Flaps, Regenerative Therapy & Furcation Management 9.4 Supportive Periodontal Care, Maintenance Protocols & Risk Re-evaluation

10 Chapter 10: Preventive Dentistry

10.1 Caries Risk Assessment Models (CAMBRA) & Personalised Prevention 10.2 Fluoride Mechanisms, Topical Applications & Community Fluoridation 10.3 Dietary Counselling, Stephan Curve Dynamics & Erosion Prevention 10.4 Pit and Fissure Sealants, Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP)

11 Chapter 11: Dental Emergencies

11.1 Emergency Management of Severe Odontogenic Pain & Acute Irreversible Pulpitis 11.2 Acute Management of Avulsed, Luxated & Fractured Permanent Teeth 11.3 Diagnosis, Differentiation & Treatment of Cracked Tooth Syndrome 11.4 Emergency Management of Post-Extraction Hemorrhage & Acute Abscesses

12 Chapter 12: Pain & Behaviour Management

12.1 Assessment & Management of Dental Anxiety, Phobia & Dental Fear 12.2 Nitrous Oxide Inhalation Sedation & Intravenous Sedation Guidelines 12.3 Diagnosis & Management of Temporomandibular Disorders & Chronic Facial Pain 12.4 Informed Consent, Patient Autonomy, Ethics & Professional Boundaries

13 Chapter 13: Removable Prosthodontics

13.1 Complete Denture Design, Impression Techniques & Maxillomandibular Relations 13.2 Removable Partial Denture Design, Surveying, Clasping & RPI System 13.3 Post-Insertion Problems, Sore Spots, Relining & Rebase Procedures 13.4 Denture Stomatitis, Tissue Conditioning & Pre-Prosthetic Surgery

14 Chapter 14: Dental Radiography & Imaging

14.1 Radiation Physics, ALARA Principles, Shielding & Dose Reduction 14.2 Intraoral Radiographic Techniques, Positioning & Geometry 14.3 Radiographic Interpretation, Normal Anatomical Landmarks & Artifacts

15 Chapter 15: Infection Prevention & Control

15.1 Standard & Transmission-Based Precautions in Dental Practice 15.2 Instrument Reprocessing, Autoclaving & Sterilisation Monitoring 15.3 Dental Unit Waterlines, Waste Management & Occupational Exposure Protocols

16 Chapter 16: Dental Implants & Peri-Implant Diseases

16.1 Patient Selection, Bone Density, Anatomic Constraints & Prosthetic Planning 16.2 Peri-Implant Anatomy, Hygiene Protocols & Maintenance Monitoring 16.3 Diagnosis, Risk Factors & Management of Peri-Implant Diseases

3.5 Medication-Related Osteonecrosis of the Jaw (MRONJ) Risk & Management

Key Takeaways Explain This Topic AI

MRONJ diagnostic criteria require exposed bone or bone probed through a fistula persisting >8 weeks, current/prior exposure to antiresorptive or anti-angiogenic agents, and NO history of radiation therapy or metastatic disease in the jaws.

Oncology patients receiving high-dose intravenous bisphosphonates or monthly subcutaneous Denosumab carry a significantly higher risk of MRONJ (1-15%) compared to osteoporosis patients (<0.1%).

Stage 1 MRONJ consists of exposed bone or fistula without pain or infection and is managed conservatively with 0.12-0.2% Chlorhexidine mouthwash.

Stage 2 MRONJ involves exposed bone with pain and systemic infection, requiring systemic oral antibiotics alongside antimicrobial rinses and superficial debridement.

Drug holidays for bisphosphonates are not routinely supported by clinical evidence due to long-term skeletal accumulation; Denosumab drug holidays carry severe risks of rebound vertebral fractures.

Last updated: August 2026

3.5 Medication-Related Osteonecrosis of the Jaw (MRONJ) Risk & Management

Medication-Related Osteonecrosis of the Jaw (MRONJ) is a severe, potentially debilitating drug-induced osteonecrosis affecting the maxilla and mandible. Dentists playing a critical role in pre-therapy dental clearance, risk mitigation, early diagnosis, and conservative surgical management according to guidelines established by the Australian Dental Association (ADA) and American Association of Oral and Maxillofacial Surgeons (AAOMS).

Diagnostic Criteria for MRONJ

To establish a clinical diagnosis of MRONJ, all three of the following criteria must be satisfied:

Exposed Bone or Fistula : Current exposed bone in the maxillofacial region OR intraoral/extraoral bone that can be probed through a fistula, persisting for more than 8 weeks .

Pharmacological Exposure : Current or prior treatment with antiresorptive agents (bisphosphonates, denosumab) or anti-angiogenic therapies .

Absence of Radiation / Metastasis : No history of radiation therapy to the jawbones and no primary metastatic disease involving the jaws. +---------------------------------------------------------------------------------------------------+

  • | MRONJ DIAGNOSTIC TRIAD REQUIREMENT |
  • | |
  • | Exposed Bone / Probed Fistula > 8 Weeks + Antiresorptive / Anti-Angiogenic Drug History |
  • | + |
  • | NO Prior Radiation Therapy to Jaws / NO Local Metastasis |
  • +---------------------------------------------------------------------------------------------------+
  • Pharmacological Classes Implicated in MRONJ
  • 1. Antiresorptive Agents

Bisphosphonates : Synthetic analogues of inorganic pyrophosphate that bind selectively to hydroxyapatite crystals in bone matrix. During osteoclastic bone resorption, bisphosphonates are internalized by osteoclasts, inhibiting farnesyl pyrophosphate (FPP) synthase, triggering osteoclast apoptosis and suppressing bone remodeling.

Oral Formulations (Osteoporosis) : Alendronate (Fosamax), Risedronate (Actonel), Ibandronate .

Intravenous Formulations (Oncology / Bone Metastases) : Zoledronic Acid (Zometa 4 mg IV monthly for oncology; Aclasta 5 mg IV annually for osteoporosis), Pamidronate .

RANKL Inhibitors : Denosumab is a human monoclonal antibody that binds to receptor activator of nuclear factor kappa-B ligand (RANKL), preventing RANKL from activating RANK on osteoclasts.

Prolia : 60 mg subcutaneous injection every 6 months (Osteoporosis indication; lower risk profile).

Xgeva : 120 mg subcutaneous injection monthly (Bone metastases / Multiple myeloma; high risk profile).

2. Anti-Angiogenic Agents

Interfere with vascular endothelial growth factor (VEGF) signaling pathways, impairing new vessel formation and bone vascularity (e.g., Bevacizumab , Sunitinib , Sorafenib ).

Patient Risk Stratification

The risk of developing MRONJ varies dramatically based on therapeutic indication, drug potency, cumulative dose, and route of administration.

Risk Category Clinical Indication & Drug Exposure Estimated Incidence Primary Risk Factors

Low Risk Oral Bisphosphonates for Osteoporosis ( < 4 <4 < 4 years duration); Subcutaneous Denosumab (Prolia 60 mg 6-monthly < 4 <4 < 4 years) 0.01% – 0.1% (1 in 1,000 to 1 in 10,000) Duration < 4 <4 < 4 yrs, no systemic corticosteroids or co-morbidities

High Risk IV Bisphosphonates (Zometa) or High-Dose Denosumab (Xgeva) for Oncology; Oral Antiresorptives > 4 >4 > 4 years; Concurrent systemic Corticosteroid use 1% – 15% (1 in 100 to 1 in 7) Dentoalveolar surgery (extractions ~60-70% of triggers), poor oral hygiene, ill-fitting dentures, anemia, diabetes KEY TAKEAWAY ON RISK:

Oncology regimens (monthly IV Zoledronic acid or monthly Denosumab) carry a risk up to

100-fold HIGHER than standard oral osteoporosis therapy.

Clinical Staging & Management Protocols (AAOMS / ADA)

Stage Clinical & Radiographic Presentation Recommended Management Protocol

At Risk No exposed bone, asymptomatic; patient taking antiresorptives Patient education, oral hygiene optimization, routine dental care

Stage 0 No clinical bone exposure, but non-specific symptoms (unexplained jaw pain, loose teeth, sinus pain, altered bone density) Conservative symptom management, radiographic monitoring, pain control

Stage 1 Exposed necrotic bone or fistula probing to bone; Asymptomatic with No evidence of infection or swelling Topical antimicrobial mouthwashes ( 0.12–0.2% Chlorhexidine bid); regular clinical follow-up; avoid operative intervention

Stage 2 Exposed bone or fistula probing to bone WITH Pain, Erythema, and Local Infection (with/without purulent drainage) Oral Systemic Antibiotics (e.g., Amoxicillin 500 mg tid + Metronidazole 400 mg tid) + 0.2% Chlorhexidine + superficial soft tissue debridement

Stage 3 Exposed bone extending beyond alveolar bone (inferior border, ramus, maxillary sinus), Pathological Fracture , extraoral fistula, or oroantral communication Surgical Debridement / Resection , IV antibiotics, pain management, microvascular reconstruction

  • Pre-Therapy Dental Clearance & Prevention Strategies
  • Patients About to Initiate High-Dose Antiresorptive / Oncology Therapy

Comprehensive Examination : Full clinical and radiographic assessment (Bitewing and OPG/CBCT).

Eliminate Foci of Infection : Extract non-restorable teeth, teeth with poor periodontal prognosis (probing depths > 6 mm >6\text{ mm} > 6 mm , mobility class II/III), and hopeless impacted molars.

Allow Mucosal Healing : Delay commencement of oncology antiresorptive therapy for 14 to 21 days post-extraction to allow complete epithelialisation and primary mucosal closure over socket sites.

Prophylaxis & Hygiene : Perform full-mouth scaling, restorative care, and patient oral hygiene instruction.

Patients Currently Receiving Antiresorptive Therapy Requiring Dental Procedures

Prefer Non-Invasive Procedures : Endodontic therapy (with coronal tooth sectioning if non-restorable) is strongly preferred over tooth extraction to avoid bone exposure.

Preventive Surgical Protocol (If Extraction Unavoidable) :

Perform atraumatic exodontia with minimal periosteal elevation.

Smooth sharp alveolar bone margins (alveoloplasty) to eliminate bony spicules.

Achieve primary mucosal closure without tension using resorbable sutures.

Administer perioperative antibiotic prophylaxis (e.g., Amoxicillin 500 mg 8-hourly starting 24h prior and continuing 5-7 days post-operatively).

Prescribe 0.2% Chlorhexidine mouthwash twice daily for 2 weeks.

The "Drug Holiday" Controversy

Bisphosphonates : Bisphosphonates bind irreversibly to bone mineral and persist in the skeleton for up to 10 years. Discontinuing oral bisphosphonates for short periods ("drug holiday") prior to dental surgery provides no proven reduction in MRONJ risk .

Denosumab : Denosumab does not incorporate into bone matrix; its antiresorptive effects wane rapidly 6 months after injection. However, initiating a drug holiday from Denosumab triggers a rebound surge in osteoclast activity , leading to rapid bone loss and severe risk of multiple rebound vertebral fractures . Denosumab therapy must NEVER be interrupted without explicit consultation with the patient's endocrinologist/oncologist.

Loading diagram... MRONJ Clinical Staging and Management Decision Tree